个性鲜明的短视频龙头，持续打造超级商业综合体 需求有望逐季改善 规模提升叠加数字化转型，有望带动全年业绩增长 1Q22 review: results in line, propose to issue TLAC instruments in late FY22 新校区建成扩容，湾区发展红利显著 Challenges yet over, but LT fundamentals intact Excellent 1Q22 and a brighter 2Q22E outlook FDA raised the bar for the approval of surufatinib FY21 & 1Q22 review: results in line, asset quality improved Strategic expansion to the upstream experimental model supply